Design and optimization of orally spleen tyrosine kinase (SYK) inhibitors for treatment of solid tumor.

Cheng Wang, Xin Wang, Yao Li, Tianqi Wang, Zhi Huang, Zhongxiang Qin, Shengyong Yang, Rong Xiang, Yan Fan

Bioorganic chemistry 2020 Jan

filter terms:

As the aim to discover orally SYK inhibitors for solid tumor treatment, a series of novel derivatives based on imidazo[1,2-a]pyrazine scaffold were designed, synthesized and evaluated. Structure-activity relationship study of both enzymatic and cellular assays led to the identification of compound 12f. The novel SYK inhibitor 12f showed potent antitumor activity against solid tumors with favorable drug-like properties of lipophilicity and solubility. 12f could induce cell apoptosis of ovarian and lung cancer cell lines. In SKOV3 xenograft mouse model, oral administration of 12f led to significant tumour regression without obvious toxicity. 12f improved the limited response of traditional SYK inhibitors in solid tumors in vitro and in vivo. Taken together, this compound may act as a promising lead compound for further development of new SYK inhibitors for solid tumor therapy. Copyright © 2019 Elsevier Inc. All rights reserved.

Citation

Cheng Wang, Xin Wang, Yao Li, Tianqi Wang, Zhi Huang, Zhongxiang Qin, Shengyong Yang, Rong Xiang, Yan Fan. Design and optimization of orally spleen tyrosine kinase (SYK) inhibitors for treatment of solid tumor. Bioorganic chemistry. 2020 Jan;95:103547